Orion - Company Announcement

President and CEO Timo Lappalainen today at Annual General Meeting of Orion Corporation: Orion's sales developed well in early 2011

ORION CORPORATION STOCK EXCHANGE RELEASE 31 March 2011 at 12.05 p.m. EEST

Orion Corporation is holding its Annual General Meeting today, March 31, 2011,
at 2.00 p.m. EEST. President and CEO Timo Lappalainen will present a review of
Orion's year 2010. In his presentation Mr. Lappalainen will mention that Orion's
sales have developed well in early 2011, which indicates a strong result for Q1
2011.

The complete agenda of the AGM was published on March 9, 2011, and it is
available on the company website at www.orion.fi. The materials of the review of
the President and CEO Timo Lappalainen are available on the company website
latest on the following day.

The decisions of the AGM will be communicated in a stock exchange release later
today, after the meeting.

Orion will publish the Interim Report January-March 2011 on Wednesday, 27 April
2011.



Orion Corporation


Timo Lappalainen   Olli Huotari
President and CEO  SVP, Corporate Functions



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi

Orion is an innovative European R&D-based pharmaceutical and diagnostic company
with a special emphasis on developing medicinal treatments and diagnostic tests
for global markets. Orion develops, manufactures and markets human and
veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic
tests. Orion's pharmaceutical R&D focuses on the following core therapy areas:
central nervous system drugs, cancer and critical care drugs, and Easyhaler®
pulmonary drugs.

The Group's net sales in 2010 amounted to approximately EUR 850 million. The
Company invested EUR 85 million in research and development. At the end of
2010, the Group had a total of approximately 3,100 employees, of whom 2,450
worked in Finland and 650 in other European countries. Orion's A and B shares
are listed on NASDAQ OMX Helsinki.




[HUG#1501963]